Read by QxMD icon Read

Urologic Oncology

Ioannis Lilis, Ioanna Giopanou, Helen Papadaki, Kostis Gyftopoulos
BACKGROUND: Mammalian target of rapamycin (mTOR) is a central regulator of major cellular processes such as growth and proliferation. Deregulated mTOR signaling is implicated in a wide spectrum of human malignancies including prostate cancer. The aim of this study is to address the role of phosphorylated mTOR (p-mTOR) in prostate adenocarcinoma-induced lymphangiogenesis and lymph node metastasis as well as to investigate its relationship with chicken ovalbumin upstream promoter transcriptional factor 2 (COUP-TFII) and the vascular endothelial growth factors A/C (VEGF A/C)...
March 12, 2018: Urologic Oncology
Rita Azevedo, Janine Soares, Andreia Peixoto, Sofia Cotton, Luís Lima, Lúcio Lara Santos, José Alexandre Ferreira
CONTEXT: Circulating tumor cells (CTC) in peripheral blood of cancer patients provide an opportunity for real-time liquid biopsies capable of aiding early intervention, therapeutic decision, response to therapy, and prognostication. Nevertheless, the rare and potentially heterogeneous molecular nature of CTC has delayed the standardization of robust high-throughput capture/enrichment and characterization technologies. OBJECTIVE: This review aims to systematize emerging solutions for CTC analysis in bladder cancer (BC), their opportunities and limitations, while providing key insights on specific technologic aspects that may ultimately guide molecular studies and clinical implementation...
March 9, 2018: Urologic Oncology
Naoya Niwa, Eiji Kikuchi, Kazuhiro Matsumoto, Takeo Kosaka, Ryuichi Mizuno, Mototsugu Oya
PURPOSE: It is still unknown whether switching the bacillus Calmette-Guérin (BCG) strain at the second induction course of BCG therapy has a therapeutic benefit in patients with tumor recurrence after the initial BCG therapy (BCG-relapsing tumor). MATERIALS AND METHODS: We retrospectively reviewed the clinicopathological features of 97 patients treated with a second induction course of BCG therapy between 1986 and 2014. Among the patients initially treated with BCG Tokyo-172, the second course was either BCG Tokyo-172 in 56 (57...
March 9, 2018: Urologic Oncology
Jennifer B Gordetsky, Benjamin Saylor, Sejong Bae, Jeffrey W Nix, Soroush Rais-Bahrami
OBJECTIVES: To assess management choices in patients who undergo magnetic resonance imaging (MRI)/ultrasound (MRI/US) fusion-guided prostate biopsy compared to patients who undergo systematic biopsy. METHODS: We compared men who underwent MRI/US fusion-guided prostate biopsy to those who underwent systematic 12-core biopsy from 2014 to 2016. Patient demographics and pathologic findings were reviewed. The highest grade group per case was considered for analysis. RESULTS: Follow-up was available on 133 patients who underwent MRI/US targeted biopsy and 215 patients who underwent systematic biopsy...
March 8, 2018: Urologic Oncology
Islam M El-Babouly, Esam A E Desoky, Diab El Sayed, Maged M Ali, Ola A Harb, Ahmed Ragab, Ahmed M Sakr, Amr M Fawzi, Nashaat M Salama, Ibrahim I Samaha
OBJECTIVE: To report the sensitivity and specificity of neural precursor cell-expressed developmentally down-regulated protein 9 (NEDD9) protein high expression in predicting BCG response and its effect on recurrence or progression free survivals. PATIENTS AND METHODS: Between May 2014 and April 2017, a prospective cohort study was conducted on 105 patients with intermediate or high-risk nonmuscle invasive bladder cancer. Immunohistochemical staining with mouse monoclonal anti-NEDD9 antibody was done...
March 5, 2018: Urologic Oncology
David D Andrea, Mohammad Abufaraj, Martin Susani, Robin Ristl, Beat Foerster, Shoji Kimura, Andrea Mari, Francesco Soria, Alberto Briganti, Pierre I Karakiewicz, Killian M Gust, Morgan Rouprêt, Shahrokh F Shariat
PURPOSE: To improve current prognostic models for the selection of patients with T1G3 urothelial bladder cancer who are more likely to fail intravesical therapy and progress to muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: We performed a retrospective analysis of 1,289 patients with pT1G3 urothelial bladder cancer who were treated with transurethral resection of the bladder (TURB) and adjuvant intravesical bacillus-Calmette-Guérin (BCG). Random-split sample data and competing-risk regression were used to identify the independent impact of lymphovascular invasion (LVI) and variant histology (VH) on progression to MIBC...
March 2, 2018: Urologic Oncology
Nicolas von Landenberg, Atiqullah Aziz, Friedrich C von Rundstedt, Jakub Dobruch, Luis A Kluth, Andrea Necchi, Aidan Noon, Michael Rink, Kees Hendricksen, Karel P J Decaestecker, Roland Seiler, Cédric Poyet, Harun Fajkovic, Shahrokh F Shariat, Evanguelos Xylinas, Florian Roghmann
OBJECTIVE: To determine conditional recurrence-free survival (RFS) and progression-free survival (PFS) and improve decision-making toward surveillance protocols and scheduling. Furthermore, evaluating the evolution of predictors for disease recurrence over time, because TaG1 non-muscle-invasive bladder cancer harbors a risk of disease recurrence and progression. MATERIAL AND METHODS: The retrospective multicenter design study includes 1,245 TaG1 bladder cancer patients with median follow-up of 62...
March 2, 2018: Urologic Oncology
Shaojin Zhang, Juanjuan He, Zhankui Jia, Zechen Yan, Jinjian Yang
BACKGROUND: Acetyl-CoA synthetase 2 (ACSS2) is highly expressed in various cancers, whereas ACSS2 expression and function in renal cell carcinoma (RCC) are unknown. METHODS: We investigated ACSS2 expression in 198 human RCC tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance. Overexpression and knockdown of ACSS2 were used to investigate the proliferation, migration and invasion of human RCC 786-O, 769-P, and ACHN cell lines...
March 1, 2018: Urologic Oncology
Christopher J D Wallis, Raj Satkunasivam, Sender Herschorn, Calvin Law, Arun Seth, Ronald T Kodama, Girish S Kulkarni, Robert K Nam
BACKGROUND: Androgen-deprivation therapy (ADT) has been associated with cardiovascular risk factors and the development of cardiovascular disease in men with metastatic prostate cancer. We sought to examine the effect of ADT on nonprostate cancer mortality among patients with nonmetastatic prostate cancer. METHODS: We performed a population-based, retrospective cohort study of men aged 66 years and older treated with surgery or radiotherapy for nonmetastatic prostate cancer in Ontario, Canada from 2002 to 2009 using administrative datasets (including the Ontario Cancer Registry, Ontario Drug Benefit, and Ontario Health Insurance Plan)...
March 1, 2018: Urologic Oncology
Johannes Falke, Christina A Hulsbergen-van de Kaa, Roberto Maj, Egbert Oosterwijk, Johannes Alfred Witjes
OBJECTIVES: To evaluate and compare the pharmacokinetic and pharmacodynamic properties of 2 investigational Toll-like receptor 7 agonists, TMX-101, and TMX-202 after intravenous and intravesical administration in a rat model. TLR-7 agonists are successfully used as topical treatment for various (pre)malignant skin lesions and are now under investigation as intravesical therapy for non-muscle-invasive bladder cancer. METHODS: Rats received an intravesical instillation with TMX-101, TMX-202, or vehicle...
February 27, 2018: Urologic Oncology
Ye Wang, Matthew Mossanen, Steven L Chang
OBJECTIVE: Urologic cancers are not only among the most common types of cancers, but also among the most expensive cancers to treat in the United States. This study aimed to review the use of CEAs and other cost analyses in urologic oncology using large databases to better understand the value of management strategies of these cancers. METHODS: A literature review on CEAs and other cost analyses in urologic oncology using large databases. RESULTS: The options for and costs of diagnosing, treating, and following patients with urologic cancers can be expected to rise in the coming years...
February 27, 2018: Urologic Oncology
Tahlita C M Zuiverloon, Kim E M van Kessel, Trinity J Bivalacqua, Joost L Boormans, Thorsten H Ecke, Petros D Grivas, Anne E Kiltie, Fredrik Liedberg, Andrea Necchi, Bas W van Rhijn, Florian Roghmann, Marta Sanchez-Carbayo, Bernd J Schmitz-Dräger, Felix Wezel, Ashish M Kamat
RATIONALE: Several guidelines exist that address treatment of patients with nonmetastatic muscle-invasive bladder cancer (MIBC). However, most only briefly mention follow-up strategies for patients and hence the treating physician is often left to infer on what the preferred follow-up schema would be for an individual patient. Herein, we aim to synthesize recommendations for follow-up of patients with MIBC for easy reference. METHODS: A multidisciplinary MIBC expert panel from the International Bladder Cancer Network was assembled to critically assess currently available major guidelines on surveillance of MIBC patients...
February 26, 2018: Urologic Oncology
Michael L Cheng, Gopa Iyer
A sea change has occurred in the treatment options available for metastatic urothelial bladder cancer with the recent Food and Drug Administration approval of 5 immune checkpoint blockade agents for patients who have progressed on platinum-based chemotherapy or are not candidates for cisplatin. Additionally, comprehensive characterization of the landscape of genomic alterations in this disease through The Cancer Genome Atlas and other efforts has detected numerous potential targets for small molecule inhibitors...
February 19, 2018: Urologic Oncology
Ted A Skolarus
No abstract text is available yet for this article.
February 15, 2018: Urologic Oncology
Sean A Fletcher, Philipp Gild, Alexander P Cole, Malte W Vetterlein, Adam S Kibel, Toni K Choueiri, Guru P Sonpavde, Mark A Preston, Daniel Pucheril, Mani Menon, Maxine Sun, Stuart R Lipsitz, Quoc-Dien Trinh
OBJECTIVES: Healthcare for racial minorities is densely concentrated at a small subset of hospitals in the United States. Understanding long-term outcomes at these minority-serving hospitals is highly relevant to elucidating the sources of racial disparities in cancer care. We investigated the effect of treatment at a minority-serving hospital on overall survival and receipt of definitive treatment for bladder cancer. MATERIALS AND METHODS: Using the National Cancer Database, we identified all patients diagnosed with clinically localized, muscle-invasive bladder cancer between 2004 and 2012...
February 14, 2018: Urologic Oncology
Tarik Benidir, Karen Hersey, Antonio Finelli, Rob Hamilton, Anthony M Joshua, Girish Kulkarni, Alexandre Zlotta, Neil Fleshner
Several new compounds are now available for castration resistant prostate cancer (CRPC). Individual costs range between $40,000 and $93,000 with mean survival extensions from 2.4 to 4.8 months. Currently, it remains unclear how patients with prostate cancer (PCa) value the effect of these therapies in the setting of CRPC. OBJECTIVE: To assess patient understanding of core cancer concepts, opinions on the cost and overall benefit of CRPC drugs, whether out-of-pocket costs would change opinions and whether patients would ultimately opt out of CRPC drug treatment for an end-of-life (EOL) premium...
February 14, 2018: Urologic Oncology
Neelam Mukherjee, Robert S Svatek, Ahmed M Mansour
Intravesical instillation of live attenuated bacillus Calmette-Guérin (BCG) is the gold standard for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). BCG-failures include a heterogenous population of patients who share a designation of disease recurrence or progression following BCG and include patients with complete unresponsiveness to BCG, patients who respond initially but develop relapse and, in some cases, patients who are intolerant to BCG due to side effects. Given the efficacy and relatively rapid approval of several monoclonal antibodies against PD-L1 or PD-1 for advanced and metastatic bladder cancer, the role of these checkpoint inhibitors in BCG-relapsing disease at various disease stages is under consideration...
February 8, 2018: Urologic Oncology
Giorgio I Russo, Sebastiano Cimino, Giorgia Giranio, Federica Regis, Vincenzo Favilla, Salvatore Privitera, Fabio Motta, Rosario Caltabiano, Arnulf Stenzl, Tilman Todenhöfer, Giuseppe Morgia
INTRODUCTION AND OBJECTIVES: To evaluate the association between metabolic syndrome (MetS) and proliferative inflammatory atrophy (PIA) in patients with suspected prostate cancer (PCa). PATIENTS AND METHODS: From June 2015 to July 2016, we conducted the FIERY (Flogosis Increased Events of pRostatic biopsY) study at the Urology section, Department of Surgery of the University of Catania (Local registration number: #131/2015). A total of 205 patients with elevated prostate-specific antigen (≥ 4 ng/ml) or clinical suspicion of PCa who underwent primary transperineal prostate biopsy were included in this cross-sectional study...
February 8, 2018: Urologic Oncology
Michelle L McDonald, Lauren E Howard, William J Aronson, Martha K Terris, Matthew R Cooperberg, Christopher L Amling, Stephen J Freedland, Christopher J Kane
OBJECTIVE: To analyze factors associated with metastases, prostate cancer-specific mortality, and all-cause mortality in pN1 patients. MATERIALS AND METHODS: We analyzed 3,642 radical prostatectomy patients within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Pathologic Gleason grade, number of lymph nodes (LN) removed, and first postoperative prostate-specific antigen (PSA) (<0.2 ng/ml or ≥0.2 ng/ml) were among covariates assessed. Cox regression was used to analyze the association between characteristics and survival outcomes...
February 8, 2018: Urologic Oncology
Rick Bangs, Tony Crispino
This article provides the patient perspective on cancer clinical trials.
February 7, 2018: Urologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"